IAG & Takeda Partner in Ulcerative Colitis Histopathological Image Analysis
The objective of the collaboration is to develop and validate an artificial intelligence (AI) powered tool that will potentially allow gastroenterologists to effectively incorporate histology (the study of the microscopic structure of tissues) in their real-life assessment of people suffering from UC.
In this collaboration, the parties will utilize an AI-driven approach to augment clinical decision making when assessing disease activity and the efficacy of treatments in UC. The parties will focus on the validation of the use of deep learning models and the use of IAG’s methodologies and platform DYNAMIKA in automating the assessment of UC histopathological images.
With support from the world’s leading clinical research opinion leaders and experienced pathologists, IAG will develop a seamless workflow to process and analyze the imaging data and provide expertise in using deep learning and AI and apply these models to the imaging data analysis.
Prof. Laurent Peyrin-Biroulet, Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, the scientific lead on this project, said “The success of patient treatment with novel therapeutic agents highly depends on the efficient use of modern technologies and data-centric development approaches. In such a critical area as IBD, our patients will no doubt will benefit from the use of Artificial Intelligence to augment clinical decisions.“
“With results from recent clinical trials and emerging concepts of response to treatment such as disease clearence, there is a growing need to look at the disease through a different lens and ideally in a combined and holistic way. In real life, there are barriers in terms of access to trained IBD Pathologists. With its focus on automated quantitative imaging-driven analytics, this collaboration is a step towards putting assessment tools in the hands of practicing gastroenterologists, which will ultimately benefit patients“, added Dr. Andrea Stancati M.D., Vice President, Global Medical Franchise Head, Gastroenterology at Takeda.
“We believe in demystifying AI and making it truly useful in the clinical decision making and clinical research”, said Dr. Olga Kubassova, CEO if IAG, “IAG is uniquely positioned to provide tools which could be a game-changer, particularly for the development and use of advanced therapies in complex areas such as IBD, ultimately supporting the goal of getting the right treatment to the right patients at the right time.”
About IAG, Image Analysis Group
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com
About Takeda Pharmaceutical Company Limited